Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
PAVmed Inc is a medical devices business based in the US. PAVmed shares (PAVM) are listed on the NASDAQ and all prices are listed in US Dollars. PAVmed employs 15 staff and has a market cap (total outstanding shares value) of USD$110.1 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$1.76 |
---|---|
52-week range | USD$1.14 - USD$3.45 |
50-day moving average | USD$1.8944 |
200-day moving average | USD$1.9639 |
Wall St. target price | USD$5.08 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.647 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.76 from 2020-12-18
1 week (2021-01-08) | -17.37% |
---|---|
1 month (2020-12-16) | -8.33% |
3 months (2020-10-15) | -11.56% |
6 months (2020-07-15) | -15.79% |
1 year (2020-01-15) | 28.47% |
---|---|
2 years (2019-01-15) | 83.33% |
3 years (2018-01-12) | 2.96 |
5 years (2016-01-12) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -170.89% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | $-0.108 |
Market capitalisation | USD$110.1 million |
TTM: trailing 12 months
There are currently 3.7 million PAVmed shares held short by investors – that's known as PAVmed's "short interest". This figure is 15.7% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting PAVmed shares can be evaluated.
PAVmed's "short interest ratio" (SIR) is the quantity of PAVmed shares currently shorted divided by the average quantity of PAVmed shares traded daily (recently around 1.4 million). PAVmed's SIR currently stands at 2.67. In other words for every 100,000 PAVmed shares traded daily on the market, roughly 2670 shares are currently held short.
However PAVmed's short interest can also be evaluated against the total number of PAVmed shares, or, against the total number of tradable PAVmed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PAVmed's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 PAVmed shares in existence, roughly 60 shares are currently held short) or 0.0738% of the tradable shares (for every 100,000 tradable PAVmed shares, roughly 74 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PAVmed.
Find out more about how you can short PAVmed stock.
We're not expecting PAVmed to pay a dividend over the next 12 months.
Over the last 12 months, PAVmed's shares have ranged in value from as little as $1.14 up to $3.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PAVmed's is 0.1132. This would suggest that PAVmed's shares are less volatile than average (for this exchange).
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.